Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T06841 | ||||
| Target Name | Interleukin-23 (IL23) | ||||
| Synonyms | UNQ2498/PRO5798; SGRF; P40 subunit of interleukin-23; Interleukin-23 subunit p19; Interleukin-23 subunit alpha; Interleukin 23 subunit alpha; IL-23p19; IL-23-A; IL-23 subunit alpha; IL-23 | ||||
| Target Type | Successful | ||||
| Gene Name | IL23A | ||||
| Biochemical Class | Cytokine: interleukin | ||||
| UniProt ID | IL23A_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Psoriasis | ||||
| Example drug | Ustekinumab | Approved | [1], [2], [3], [4] | ||
| Tissue | Skin | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.07 Z-score: -0.27 P-value: 9.54E-04 |
||||
| Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: 0.57 Z-score: 3.79 P-value: 3.22E-52 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Asthma | ||||
| Example drug | CNTO-1959 | Phase 3 | [5], [3], [4] | ||
| Tissue | Nasal and bronchial airway | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.11 Z-score: -0.37 P-value: 1.84E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Rheumatoid arthritis | ||||
| Example drug | CNT0-1959 | Phase 2 | [6], [3], [4] | ||
| Tissue | Synovial tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.1 Z-score: -0.42 P-value: 5.37E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target's Expression Profile across Various Tissues of Healthy Individual | |||||
|
|||||
| References | |||||
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6885). | ||||
| REF 2 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. | ||||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 4 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018 | ||||
| REF 6 | Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy in Treatment of Moderate to Severe Plaque Psoriasis. Janssen Research & Development, LLC (Janssen). Mar 24, 2014. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.